Clinical trial · Interventional
Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program
NCT01786031CI-TRIAL-00020821PETRUScompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Toward personalised treatment in early metastatic prostate cancer based on the assessment of biomarkers in cancer tissue samples and circulating tumour cells.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Castration Resistant Prostate Cancer Patients | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| metastasis biopsy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- experimental
- description
- metastasis biopsy
- interventionNames
- Other: metastasis biopsy
Primary outcomes (1)
- measure
- Biomarker
- timeFrame
- assessed at the end of recruitment, up to 2 years
- description
- success to evaluate at least one molecular analysis in tumor tissues (prostate and/or metastatic site) AND in CTC
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Prostate Cancer patients * Castration Resistant * Prostatic tissue available * Metastasis which may be biopsied Exclusion Criteria:
References
Publications (1)
- DERIVEDLindsay CR, Le Moulec S, Billiot F, Loriot Y, Ngo-Camus M, Vielh P, Fizazi K, Massard C, Farace F. Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer. BMC Cancer. 2016 Feb 29;16:168. doi: 10.1186/s12885-016-2192-6. PMID 26923772